{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380021392644898567.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Martina Fähndrich"}],"foaf:familyName":[{"@value":"Fähndrich"}],"foaf:givenName":[{"@value":"Martina"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360021392644898560","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.26226/m.63185c4d7e215f5e7f3850b5"}],"notation":[{"@value":"Long-term improvements in disease severity, itch, and QoL after 3 years of tralokinumab treatment in adults with moderate-to-severe AD"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.26226/m.63185c4d7e215f5e7f3850b5_ZcwaG5WBbjvAbbkchbpCtdoYiCd"}]}